Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InMed PharmaceuticalsINM -7.59%32 Equity-to-Asset is 0.76 as of Mar. 2026, which is 11% below its 10-year median of 0.85. GuruFocus rates INM with a GF Score™ of 32/100 and a GF Value™ of $0.91 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, InMed Pharmaceuticals ranks better than 74.73% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
InMed Pharmaceuticals Equity-to-Asset Related Terms
InMed Pharmaceuticals Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for InMed Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INM vs APUS, GELS, YCBD: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InMed Pharmaceuticals Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where InMed Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
InMed Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMed Pharmaceuticals (INM) has a Equity-to-Asset of 0.76 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on InMed Pharmaceuticals and its competitors. This is 11% below median its historical median of 0.85. Over the past decade, InMed Pharmaceuticals' Equity-to-Asset has ranged from 0.64 to 0.98. According to the industry distribution chart, InMed Pharmaceuticals ranks #254 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 25.3%.
Is InMed Pharmaceuticals' Equity-to-Asset too high?
InMed Pharmaceuticals' current Equity-to-Asset of 0.76 is 11% below median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 0.98. The Drug Manufacturers industry median Equity-to-Asset is 0.60. InMed Pharmaceuticals' value of 0.76 is 26.7% above this industry median. Based on the distribution chart, InMed Pharmaceuticals ranks #254 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, InMed Pharmaceuticals has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Equity-to-Asset compare to APUS and GELS?
According to the Drug Manufacturers industry distribution chart, InMed Pharmaceuticals ranks #254 out of 1005 companies for Equity-to-Asset. This puts InMed Pharmaceuticals in the upper half of its industry. The industry median Equity-to-Asset is 0.60. InMed Pharmaceuticals' value of 0.76 is 26.7% above this benchmark. Historically, InMed Pharmaceuticals' own Equity-to-Asset has ranged from 0.64 to 0.98 over the past decade. While the company's 10-year median is 0.85 vs. the industry median of 0.60, InMed Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InMed Pharmaceuticals's current Equity-to-Asset of 0.76 is 26.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on InMed Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InMed Pharmaceuticals's current Equity-to-Asset is 0.76, which is 11% below median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, InMed Pharmaceuticals (INM) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.91, compared to a current price of $1.45 — trading 59.3% above its estimated fair value. The current Equity-to-Asset is 0.76, which is 11% below median its 10-year median of 0.85 and 26.7% above the Drug Manufacturers industry median of 0.60. InMed Pharmaceuticals' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For InMed Pharmaceuticals (INM), the current Equity-to-Asset is 0.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InMed Pharmaceuticals (INM) Overvalued in 2026?
Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued.
The current stock price of $1.45 is trading 59.3% above its estimated GF Value™ of $0.91.
GuruFocus considers InMed Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for INM:
Equity-to-Asset: 0.76 (11% below median its 10-year median of 0.85)
GF Value™: $0.91 vs. price of $1.45 (59.3% above fair value)
Industry Position: 26.7% above the Drug Manufacturers median (#254 of 1005)
No single metric tells the full story. See the INM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
32GF Score
Get the complete analysis for INM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INM has been successfully added to your 
